The global Lapatinib Market is experiencing significant growth, driven by the increasing prevalence of HER2-positive breast cancer and advancements in targeted cancer therapies. According to Dataintelo, the market was valued at approximately USD 1.2 billion in 2023 and is projected to reach around USD 2.5 billion by 2032, growing at a compound annual growth rate (CAGR) of 8.2% during the forecast period.